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sion; indeed, LPA induces the expression
of various cytokines, including IL-6, IL-8,
CXCL1, and CCL2 (e.g., Palmetshofer
et al., 1999; Fang et al., 2004; Klemm
et al., 2007; C. Stortelers, unpublished
results). That LPA is a key mediator of
SMD activity is demonstrated by the
failure of SMD to evoke biological effects
in LPA receptor-negative cells (van
Meeteren et al., 2004). Thus, LPA rather
than C1P is the likely trigger of the
observed inflammatory response to Lox-
osceles SMD. Specific LPA antagonists
could be useful tools for the treatment of
bites by Loxosceles spiders.
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TO THE EDITOR
We thank the authors for presenting
these valuable comments and for giving
us the opportunity to extend the dis-
cussion limited by the format of the
paper. van Meeteren et al. (2004)
confirmed that recombinant SMDs from
Loxosceles laeta and Corynebacterium
pseudotuberculosis possessed intrinsic
lysophospholipase D activity to gener-
ate bioactive lysophosphatidic acid.
They demonstrated that SMD did not
activate mitogen-activated protein ki-
nase (ERK1/2) in receptor-deficient
B103 neuroblastoma cells, whereas
both SMDs were activating mitogen-
activated protein kinase when the same
cells expressed lysophosphatidic acid1
receptors. They also showed that bac-
terial and Loxosceles SMDs triggered
receptor internalization in HEK293
cells only when preincubated with
albumin-LPC. Lee and Lynch (2005)
extended the findings by demonstrating
that recombinant L. reclusa SMD hy-
drolzses various lysophospholipids and
identified specific histidine residues
that are essential for the enzyme
activity.
Pettus et al. (2003, 2004) in two
consequential investigations provided
evidence that ceramide-1-phosphate
(C1P) interacts directly with cytosolic
phospholipase A2 (cPLA2) acting as an
activator of cPLA2 and subsequent
inflammatory response. They deter-
mined that in A549 lung adenocarci-
noma cells, natural and endogenous
(produced by SMD) C1Ps were potent
and specific inducers of arachidonic
acid and prostanoid synthesis. The
treatment of A549 cells with SMD
resulted in a threefold increase in
arachidonic acid release. Using RNA-
mediated interference technology, Pet-
tus et al. confirmed in A549 and in
J774.1 microphages that cPLA2 was
downstream of C1P. It was also found
that in A549 cells, C1P caused translo-
cation of cPLA2 to membranes. Their in
vitro binding studies disclosed that C1P
directly binds and activate with full-
length cPLA2. Other publications re-
garding biological activities of C1P are
reviewed in details by Gomez-Munoz
(2004).
The focus of our investigation was the
expression pattern of human fibroblasts
treated with recombinant SMD to gain
insight into cellular mechanisms of
loxoscelism pathology. We observed a
dose- and time-dependent upregulation
of several cytokines (data not shown).
The pattern of continuous increase was
present up to 18 hours of treatment (data
not shown). Although we recognize the
evidence that lysophospholipase D ac-
tivity of SMD is obviously an important
factor in loxoscelism, we are not con-
vinced that the sphingomyelin–ceramide
pathway involvement in the L. reclusa
pathology can be ignored. More than
one mechanism of action is also possible
in this pathology and further investiga-
tion would benefit the understanding of
the complex immunological response
following spider envenomation.
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TO THE EDITOR
Dermatitis herpetiformis (DH) is a dis-
ease precipitated by ingestion of gluten
and characterized by IgA deposits in the
dermal papillae (Nicolas et al., 2003).
Like celiac disease, DH is one presen-
tation of gluten-sensitive enteropathy
(Zone, 2005). In susceptible indivi-
duals, ingestion of gluten leads to
elaboration of antibodies against glia-
din and transglutaminase 2 (TG2) (Ox-
entenko and Murray, 2003; Alaedini
and Green, 2005; Zone, 2005). TG2,
one of nine homologous transglutami-
nases, is an autoantigen in celiac
disease (Dieterich et al., 1997; Lorand
and Graham, 2003). Serum antibodies
against TG2 can be sensitive and
specific for DH as well as celiac disease
(Dieterich et al., 1999).
Sardy et al. (2002) hypothesized that
an autoantigen related to TG2 could
explain the presentation of DH and
reported that epidermal transglutami-
nase (TG3) deposits with IgA in perile-
sional biopsies in patients with DH. IgA
deposits can occur in regions that are
not clinically involved (Fry et al., 1978;
Zone et al., 1996). To confirm the
involvement of TG3 in DH and to
determine whether TG3 deposits are
restricted to perilesional skin, we have
raised a new goat antibody against
human TG3.
In a series of nine DH patients with
active disease, we compared direct
immunofluorescence (DIF) for IgA and
TG3 in perilesional and uninvolved
skin. We also compared serology for
TG2 and TG3 and results from DIF for
IgA and TG3 in the context of a gluten-
free diet (GFD). The protocol was
approved by our Institutional Review
Board, patients consented in writing,
and we adhered to the Declaration of
Helsinki Principles. All patients had a
diagnosis of DH established by skin
biopsy showing granular IgA and had
active disease. Adherence to GFD was
reported by patients as strict or poor.
Serum was analyzed for IgA antibo-
dies against TG2, TG3, and endomy-
sium endomysial antibody (EMA).
Semiquantitative detection of anti-TG2
and -TG3 were performed using ELISA
(INOVA Diagnostics, San Diego, CA,
and Immunodiagnostik AG, Bensheim,
Germany). EMA were detected using
indirect immunofluorescence on mon-
key esophagus (University of California
at Davis) (Unsworth, 1996). Patient age,
sex, family history, adherence to GFD,
dapsone use, and serologies for anti-
bodies against TG2, TG3, and endomy-
sium are represented in Table 1. Five
patients reported strict adherence to a
GFD. Among patients adhering to a
strict GFD, four of five (80%) were
negative by IgA ELISA for anti-TG2
antibodies and EMA. All four patients
reporting poor GFD adherence had anti-
TG2 antibodies and two of four were
positive by EMA. All five patients in the
strict GFD group were seronegative for
anti-TG3 antibodies and all four patients
in the poor GFD group were positive.
The two patients with negative EMA had
the lowest values for anti-TG2.
Polyclonal TG3 antibody
Purified TG3 expressed from a baculo-
virus system was used to produce
polyclonal antibodies in goats (Ahvazi
and Steinert, 2003). Purified TG3 was a
kind gift from Dr Bijan Ahazi. To
confirm reactivity and specificity, Wes-
tern blots were performed using the
baculovirus-produced TG3 as well as
separately cloned TG2 and TG3. Com-
plementary DNAs for TG3 and TG2
were isolated by RT-PCR from human
keratinocytes using primers published
by Sardy et al., and were sequence
confirmed. Complementary DNA was
cloned in the Invitrogen pSecTag2/
Hygro B vector, lysates were purified
using a Ni2þ column (Invitrogen,
Carlsbad, CA, USA), electrophoresed,
and transferred to nitrocellulose blots.
IgG was prepared using a Protein G
column. Western blots confirmed a
high titer against both TG3 clones.
Specificity was demonstrated by lack
of reactivity against non-transfected
human embryonic kidney lysate, re-
combinant TG2 (Figure 1), and serum
and secretory (colostral) IgA (not
shown). Further specificity was estab-
lished by lack of reactivity on IIF when
reacted with skin from three patients
with linear IgA bullous dermatosis
(Figure 2e and f), two with Henoch–-
Abbreviations: DIF, direct immunofluorescence; DH, dermatitis herpetiformis; EMA, endomysial
antibody; GFD, gluten-free diet; TG2, transglutaminase 2 or tissue transglutaminase; TG3,
transglutaminase 3 or epidermal transglutaminase
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